Biology journal bans plagiarizers, reviewers with non-institutional email addresses

87959_relDNA and Cell Biology has declared it will ban any authors who submit plagiarized manuscripts for three years, and will no longer accept suggestions of reviewers with non-institutional email addresses.

The move comes after a wave of hundreds of retractions stemming from fake peer reviews, often occurring when authors supply fake emails for suggested reviewers.

In an editorial published online October 23, editor Carol Shoshkes Reiss notes that the decision to ban authors who plagiarize material stems from a rash of recent submissions containing overlapping text: Continue reading Biology journal bans plagiarizers, reviewers with non-institutional email addresses

Taste researcher falsified data in two papers: ORI

ori-logoA federal report has found that a former University of Maryland postdoc “falsified and/or fabricated” data in two papers about taste receptors.

The Office of Research Integrity report found that Maria C.P. Geraedts manipulated bar graphs in the papers to “produce the desired result.” Both have been retracted. Geraedts left academia in 2014, and is now a science writer.

We reported on one retraction in July, “Gustatory stimuli representing different perceptual qualities elicit distinct patterns of neuropeptide secretion from taste buds,” published in The Journal of Neuroscience.

The other, “Transformation of postingestive glucose responses after deletion of sweet taste receptor subunits or gastric bypass surgery,” published in 2012 in the American Journal of Physiology Endocrinology and Metabolism, was retracted in September. Here’s the note, which cites the university’s investigation: Continue reading Taste researcher falsified data in two papers: ORI

Author with three retractions objects to mega-correction following investigation

DevelopmentWe’ve uncovered a “mega-correction for a 2010 paper in Development, posted as the result of an investigation into the first author which has already led to three retractions.

Last year, the Utrecht University investigation into Pankaj Dhonukshe found “manipulation in some form” in four papers, and concluded that he committed a “violation of academic integrity.” The investigation also led to the retraction of a 2012 Cell paper and two papers in Nature that were co-authored by Dhonukshe. 

Development began investigating the corrected paper after being contacted by one of the authors and alerted to the results of the university’s investigation. The notice includes a statement from Dhonukshe objecting to the correction. Continue reading Author with three retractions objects to mega-correction following investigation

P53 researcher submitted paper “without permission from his co-authors”

Screen Shot 2015-10-20 at 1.23.37 PM

One issue that we see pretty regularly is a paper submitted by one author without the permission of the others.

That’s what’s happened with “p53-induced Rap2B positively regulates migration in cells exposed to glucose deprivation,” published in July by Molecular Carcinogenesis. The paper looks at a protein called p53, well-known to regulate cell growth and, when mutated, cause cancer.

Here’s the pretty straightforward retraction note:

Continue reading P53 researcher submitted paper “without permission from his co-authors”

University investigating duplicated images in retracted paper

Cell MetabolismThe authors of a Cell Metabolism paper are pulling it after discovering blot images that “appear more than once in independent and unrelated experiments.” 

Just how the duplication occurred in the 2009 paper — about transcription of mitochondrial DNA — remains a mystery, the authors note:

…the reasons for the errors are still under investigation…

Meanwhile, we’ve learned that the last author on the paper — Carlos Moraes of the University of Miami — has requested a retraction for another 2013 paper in Mitochondrion, also co-authored by Tina Wenz at the University of Cologne in Germany. That paper is among multiple publications co-authored by Moraes and Wenz that have been flagged on PubPeer.

We’ve reached out to the parties involved, and received a warning from an attorney representing Wenz that if we write about Continue reading University investigating duplicated images in retracted paper

BMC investigating allegedly copied paper

logoBioMed Central is investigating a recent paper about a potential biomarker for liver cancer, which shows signs it was written using another article as a template.

According to Jeffrey Beall, who exposed the similarities between the two papers on his blog Scholarly Open Access yesterday, the paper in question is “obviously bogus,” and appears to have relied on the “template plagiarism” technique of creating a new article by modifying a previous paper’s text and data.

A spokesperson for BioMed Central, which published the allegedly “junk” paper, as Beall calls it, told us they are looking into the allegations: Continue reading BMC investigating allegedly copied paper

Prostate cancer paper flagged by ORI is retracted following PETA prompt

cover_issue_129_en_USA federal investigation into a paper on prostate cancer has now led to a retraction. In an unusual twist, it happened following a request from the animal rights group People for the Ethical Treatment of Animals (PETA).

In January, the Office of Research Integrity reported that corresponding author Dong Xiao “intentionally fabricated data” in an Oncotarget study of how a steroid inhibits the growth of prostate cancer. Xiao, a former cancer researcher at the University of Pittsburgh, claimed that he had tumor data from more mice than he did, and falsified several figures.

In July, after no sign of the retraction, a researcher at PETA followed up with the journal, Oncotarget, on behalf of the organization “and our more than 3 million members and supporters to request the immediate retraction.”

Last month, they received a reply from the publisher, which they forwarded to us:

Continue reading Prostate cancer paper flagged by ORI is retracted following PETA prompt

Former ob-gyn prof notches ninth retraction; investigation still underway

Nasser Chegini
Nasser Chegini

A retired obstetrics and gynecology professor under federal investigation for misconduct has notched his ninth retraction.

The latest retraction stems from an investigation by the University of Florida, where Nasser Chegini worked until 2012, which found fabricated data in three figures in a paper on the muscle cells that line the uterus.

The paper, “Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids,” was published in The Journal of Cellular and Molecular Medicine. It’s been cited 74 times, according to Thomson Scientific’s Web of Knowledge.

Here’s the note:

Continue reading Former ob-gyn prof notches ninth retraction; investigation still underway

“Insufficient permission” from funder resects liver disease paper

HepatologyA study on chronic liver inflammation was pulled from the journal Hepatology because of “insufficient permission by the authors’ funding institution to submit and publish the manuscript.” 

The paper, which was published in July, looked into how steatosis, the abnormal retention of fat in the liver, turns into steatohepatitis, also known as fatty liver disease. Researchers found that Treg cells play a central role in controlling the disease.

Unfortunately, the journal’s managing editor didn’t provide any information about the nature of the permission problems, and the notice doesn’t give any details.

Here it isin full:

Continue reading “Insufficient permission” from funder resects liver disease paper

Failure to reproduce key experiments retracts cancer study

Medical OncologyA group of Chinese cancer researchers has retracted a paper in Medical Oncology after they discovered that “several key experiments” were not reproducible.

The paper, “Decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer,” was published in March. It found that suppressing the enzyme ATP citrate lyase could be used to treat pancreatic cancer.

However, the authors decided to pull the paper when some of the findings couldn’t be reproduced. 

Here’s the notice:

Continue reading Failure to reproduce key experiments retracts cancer study